Results 31 to 40 of about 846,916 (323)
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. [PDF]
, 2011 MicroRNAs (miRNAs) are small ∼22nt single stranded RNAs that negatively regulate protein expression by binding to partially complementary sequences in the 3' untranslated region (3' UTRs) of target gene messenger RNAs (mRNA).
Ariyan, S +16 more
core +1 more source
The Role of P4HA1 in Multiple Cancer Types and its Potential as a Target in Renal Cell Carcinoma
Frontiers in Genetics, 2022 Background: Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) provides the majority of the catalytic site of the active P4H enzyme. Emerging evidence has revealed that P4HA1 participates in the initiation and development of several malignant tumors.
Yang Li +11 more
doaj +1 more source
Proto‐oncogenes and oncogenes in epidermal neoplasia [PDF]
Experimental Dermatology, 1995 Abstract This review briefly will focus on the role of selected proto‐onco‐genes and their activated forms during the regulation of cell proliferation, cell death and tumor formation in the epidermis. In addition, the multiple and complex functions of these proteins in normal as well as transformed cells will be discussed.
M M, Simon, G, Sliutz, T A, Luger
openaire +2 more sources
Protein palmitoylation in cancer: molecular functions and therapeutic potential
Molecular Oncology, 2023 Protein S‐palmitoylation (hereinafter referred to as protein palmitoylation) is a reversible lipid posttranslational modification catalyzed by the zinc finger DHHC‐type containing (ZDHHC) protein family.
Binhui Zhou +3 more
doaj +1 more source
DNA topoisomerases participate in fragility of the oncogene RET [PDF]
, 2013 Fragile site breakage was previously shown to result in rearrangement of the RET oncogene, resembling the rearrangements found in thyroid cancer. Common fragile sites are specific regions of the genome with a high susceptibility to DNA breakage under ...
A Ganguly +86 more
core +3 more sources
Cancer Research, 2008 Abstract Cancer cells contain multiple genetic and epigenetic abnormalities. Despite this complexity, their growth and survival can often be impaired by the inactivation of a single oncogene. This phenomenon, called “oncogene addiction,” provides a rationale for molecular targeted therapy.
I Bernard, Weinstein, Andrew, Joe
openaire +2 more sources
Targeting mTOR for cancer therapy
Journal of Hematology & Oncology, 2019 Mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. mTOR is usually assembled into several complexes such as mTOR complex 1/2 (mTORC1/2).
Hui Hua +5 more
doaj +1 more source
Adenoid cystic carcinoma: emerging role of translocations and gene fusions. [PDF]
, 2016 Adenoid cystic carcinoma (ACC), the second most common salivary gland malignancy, is notorious for poor prognosis, which reflects the propensity of ACC to progress to clinically advanced metastatic disease.
Brait, Mariana +5 more
core +3 more sources
Structural basis for the assembly of the Ragulator-Rag GTPase complex
Nature Communications, 2017 mTORC1 activity is controlled through Rag GTPases, which are anchored to the lysosome through the Ragulator. Here, the authors give molecular insights into Ragulator-Rag GTPase assembly and present the crystal structures of the Ragulator alone and in ...
Ryo Yonehara +12 more
doaj +1 more source
Nature CommunicationsMutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been approved for use in lung cancer, but resistance develops rapidly. Here we use an inhibitor, (RMC-4998) that targets RASG12C in its active, GTP-bound form, to treat KRAS ...
Panayiotis Anastasiou +15 more
doaj +1 more source